ClinicalTrials.gg
CompletedNCT03994731MIRROR RCTUpdated Jun 26, 2024Results posted

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

A Phase 4 interventional study of Pegloticase and methotrexate in Gout, sponsored by Amgen. Completed at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
5th of 14
152 · median 93
Started
2019
with 1 other
Phase 4
7 of 14
none open now
Registered
8th of 14
by date
Lead sponsor
8 of 14
Amgen

Among the 14 studies testing pegloticase in Gout, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 7 in phase 4, and was the 8th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to assess the potential for pegloticase with methotrexate (MTX) to increase the response rate seen with pegloticase alone, and to characterize the safety, tolerability and pharmacokinetics (PK) of the concomitant use of pegloticase with MTX, by comparing pegloticase co-administered with MTX to pegloticase co-administered with placebo for MTX in adults with uncontrolled gout.

Read the detailed description

Study acquired from Horizon in 2024.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • gout
  • uncontrolled gout
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give .
  2. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study.
  3. Adult men or women ≥18 years of age.
  4. Uncontrolled gout, defined as meeting the following criteria:

    • Hyperuricemia during the screening period defined as sUA ≥7 mg/dL, and;
    • Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the maximum medically appropriate dose, or with a to xanthine oxidase inhibitor therapy based on medical record review or subject interview, and;
    • Symptoms of gout including at least 1 of the following:

      • Presence of at least one tophus
      • Recurrent flares defined as 2 or more flares in the past 12 months prior to screening
      • Presence of chronic gouty arthritis
  5. Willing to discontinue any oral urate lowering therapy for at least 7 days prior to MTX dosing at Week -6 and remain off when receiving pegloticase infusions.
  6. Women of (including those with an onset of menopause \<2 years prior to screening, non-therapy-induced amenorrhea for \<12 months prior to screening, or not surgically sterile [absence of ovaries and/or uterus]) must have negative serum/urine pregnancy tests during Screening and Week -6; subjects must agree to use 2 reliable forms of during the study, one of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started ≥1 full cycle prior to Week -6 (start of MTX) and continue for 30 days after the last dose of pegloticase, or at least one ovulatory cycle after the last dose of MTX or placebo for MTX (whichever is the longest duration after the last dose of pegloticase or MTX or placebo for MTX). Highly effective contraceptive methods (with a failure rate \<1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner.
  7. Men who are not vasectomized must agree to use appropriate contraception so as to not impregnate a female partner of during the study, beginning with the initiation of MTX at Week -6 and continuing and for at least 3 months after the last dose of MTX or placebo for MTX.
  8. Able to tolerate MTX 15 mg orally for 2 weeks (Week -6 through Week -4) prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. Weight >160 kg (352 pounds) at Screening.
  2. Any serious acute bacterial infection, unless treated and completely resolved with antibiotics at least 2 weeks prior to the Week -6 Visit.
  3. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis.
  4. Current or chronic treatment with systemic agents such as MTX, azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose of other on a chronic basis (3 months or longer) would also meet exclusion criteria.
  5. History of any transplant surgery requiring maintenance immunosuppressive therapy.
  6. Known history of virus surface antigen positivity or hepatitis B DNA positivity.
  7. Known history of virus ribonucleic acid (RNA) positivity.
  8. Known history of (HIV) positivity.
  9. Glucose-6-phosphate dehydrogenase deficiency (tested at the Screening Visit).
  10. Chronic renal impairment defined as estimated (eGFR) \< 40 mL/min/1.73 m\^2 or currently on dialysis.
  11. Non-compensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled blood pressure (>160/100 mmHg) prior to Randomization at Week -4.
  12. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not on an effective form of , as determined by the Investigator.
  13. Prior treatment with pegloticase, another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.
  14. Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product.
  15. to MTX treatment or MTX treatment considered inappropriate.
  16. Known intolerance to MTX.
  17. Receipt of an drug within 4 weeks or 5 half-lives, whichever is longer, prior to MTX administration at Week -6 or plans to take an investigational drug during the study.
  18. Liver transaminase levels ( [AST] or alanine aminotransferase [ALT]) > (ULN) or albumin \< the lower limit of normal (LLN) at the Screening Visit).
  19. Chronic liver disease.
  20. White blood cell count \< 4,000/µL, hematocrit \< 32 percent, or count \< 75,000/µL.
  21. Currently receiving systemic or radiologic treatment for ongoing cancer.
  22. History of within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix.
  23. Diagnosis of osteomyelitis.
  24. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
  25. Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the study.
  26. Alcohol use in excess of 3 alcoholic beverages per week.
  27. A known intolerance to all protocol standard gout flare prophylaxis regimens (i.e. subject must be able to tolerate at least one: colchicine and/or non-steroidal anti inflammatory drugs and/or low dose prednisone ≤10 mg/day).
  28. Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed necessary by the Investigator, a chest X-ray may be performed during Screening.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Pegloticase + MTX

    Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral MTX 15 mg weekly during the Run-in Period (from Week -4 to Day 1). During the Pegloticase + Immunomodulator (IMM) Period, in addition to oral 15 mg MTX, participants receive intravenous (IV) pegloticase 8 mg administered every 2 weeks (Q2W) for a total of 26 infusions from Day 1 through the Week 50 Visit. Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for infusion reaction (IR) prophylaxis.

    Biological: Pegloticase · Drug: methotrexate · Dietary Supplement: folic acid · Drug: gout flare prophylaxis regimen · Drug: fexofenadine · Drug: acetaminophen · Drug: methylprednisolone

  • Placebo comparator
    Pegloticase + Placebo

    Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral placebo for MTX weekly during the Run-in Period (from Week -4 to Day 1). During the Pegloticase + IMM Period, in addition to oral placebo for MTX, all participants receive IV pegloticase 8 mg administered Q2W for a total of 26 infusions from Day 1 through the Week 50 Visit. Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for IR prophylaxis.

    Biological: Pegloticase · Drug: methotrexate · Drug: placebo · Dietary Supplement: folic acid · Drug: gout flare prophylaxis regimen · Drug: fexofenadine · Drug: acetaminophen · Drug: methylprednisolone

Interventions

  • BiologicalPegloticase

    IV pegloticase 8 mg Q2W

    Also known as: KRYSTEXXA®

  • Oral MTX 15 mg weekly

    Also known as: MTX

  • Drugplacebo

    Oral placebo for MTX

  • Dietary supplementfolic acid

    Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.

  • Druggout flare prophylaxis regimen

    Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.

  • For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.

  • For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.

  • For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.

06

What researchers measure

Primary outcomes

  1. Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6

    Responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre- and post-infusion sUA assessments at Weeks 20 and 22, non-infusion sUA at Weeks 21 and 23, pre-infusion sUA at Week 24 and any unscheduled sUA between Week 20 and Week 24. A participant must have had ≥ 2 sUA observations from different visits in order to be eligible as a responder. Participants meeting the stopping rule (those with a pre-infusion sUA \>6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 2 Visit stopped pegloticase dosing) were counted as non-responders.

    Time frame: Month 6 (Weeks 20, 21, 22, 23 and 24)

Secondary outcomes

  1. Percentage of sUA (sUA < 6 mg/dL) Responders During Month 12

    Responders are defined as participants achieving and maintaining sUA \<6 mg/dL for at least 80% of the time during Month 12 (Weeks 48, 50 and 52). Month 12 includes pre- and post-infusion sUA Weeks 48 and 50, pre-infusion sUA at Week 52, and any unscheduled sUA assessments done at unscheduled visits between Week 48 and 52. A participant must have had ≥ 2 sUA observations from different visits in order to be eligible as a responder. Participants meeting the stopping rule (those with a pre-infusion sUA \>6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 2 Visit stopped pegloticase dosing) were counted as non-responders.

    Time frame: Month 12 (Weeks 48, 50 and 52)

  2. Percentage of Participants With Complete Resolution of ≥ 1 Tophi at Week 52

    Percentage of participants with complete resolution of ≥ 1 tophi (using digital photography) at Week 52 in participants with tophi at baseline. Participants with resolution of ≥ 1 tophi at a visit are participants with resolution of ≥ 1 tophi at the visit (i.e. have complete response), and no progressive disease for any other tophi.

    Time frame: Baseline, Week 52

  3. Mean Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52

    HAQ-DI is a self-report functional status instrument that is filled out by the participant and measures disability over the past week via 20 questions relating to 8 domains of function: dressing, grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. The HAQ-DI ranges from 0 to 3 with higher values indicating higher disability. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values.

    Time frame: Baseline, Week 52

  4. Mean Change From Baseline HAQ Pain Score at Week 52

    The HAQ-Pain score rates the participant's pain over the past week from 0 to 100 with 0 = no pain and 100 = severe pain. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values.

    Time frame: Baseline, Week 52

  5. Mean Change From Baseline in HAQ Health Score at Week 52

    The HAQ health scale is a self-reported measure of overall health. Participants are asked to rate how they are doing, considering all the ways arthritis affects them, on a scale of 0 to 100, where 0 represents very well and 100 represents very poor. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values.

    Time frame: Baseline, Week 52

07

Results

Posted May 16, 2022

Participant flow

Run-in Period (From Week -4 to Day 1)
Participant flow — Run-in Period (From Week -4 to Day 1)
MilestonePegloticase + MTXPegloticase + Placebo
Started10052
Took at least 1 dose of mtx or placebo9851
Completed9649
Not completed43
Pegloticase + IMM Period
Participant flow — Pegloticase + IMM Period
MilestonePegloticase + MTXPegloticase + Placebo
Started9649
Completed7634
Not completed2015
Withdrew: Death20
Withdrew: Lost to follow-up36
Withdrew: Withdrawal by subject159

Outcome measures

PrimaryPercentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6

Responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre- and post-infusion sUA assessments at Weeks 20 and 22, non-infusion sUA at Weeks 21 and 23, pre-infusion sUA at Week 24 and any unscheduled sUA between Week 20 and Week 24. A participant must have had ≥ 2 sUA observations from different visits in order to be eligible as a responder. Participants meeting the stopping rule (those with a pre-infusion sUA \>6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 2 Visit stopped pegloticase dosing) were counted as non-responders.

Time frame:
Month 6 (Weeks 20, 21, 22, 23 and 24)
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
percentage of participantsPegloticase + MTXPegloticase + Placebo
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 671.0 (61.1 to 79.6)38.5 (25.3 to 53.0)
Statistical analysis
  • Pegloticase + MTX vs Pegloticase + Placebo · Cochran-Mantel-Haenszel · p = < 0.0001 (The 2-sided p-value was calculated assuming the test statistic was distributed as a standard normal random variable.) · Stratified difference in proportions: 32.31 · 95% CI 16.3 to 48.3Stratified difference (Pegloticase+MTX - Pegloticase+Placebo) is a weighted average of the difference within each stratum. Estimates from the 2 strata (tophi presence at baseline: yes, no) were combined with Cochran-Mantel-Haenszel (CMH) weights.
SecondaryPercentage of sUA (sUA < 6 mg/dL) Responders During Month 12

Responders are defined as participants achieving and maintaining sUA \<6 mg/dL for at least 80% of the time during Month 12 (Weeks 48, 50 and 52). Month 12 includes pre- and post-infusion sUA Weeks 48 and 50, pre-infusion sUA at Week 52, and any unscheduled sUA assessments done at unscheduled visits between Week 48 and 52. A participant must have had ≥ 2 sUA observations from different visits in order to be eligible as a responder. Participants meeting the stopping rule (those with a pre-infusion sUA \>6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 2 Visit stopped pegloticase dosing) were counted as non-responders.

Time frame:
Month 12 (Weeks 48, 50 and 52)
Reported as:
Number · percentage of participants
Percentage of sUA (sUA < 6 mg/dL) Responders During Month 12
percentage of participantsPegloticase + MTXPegloticase + Placebo
Percentage of sUA (sUA < 6 mg/dL) Responders During Month 1260.0 (49.7 to 69.7)30.8 (18.7 to 45.1)
Statistical analysis
  • Pegloticase + MTX vs Pegloticase + Placebo · Cochran-Mantel-Haenszel · p = 0.0003 (The 2-sided p-value was calculated assuming the test statistic was distributed as a standard normal random variable.) · Response rate difference: 29.05 · 95% CI 13.2 to 44.9response rate difference (Peg+MTX - Peg+Placebo)
SecondaryPercentage of Participants With Complete Resolution of ≥ 1 Tophi at Week 52

Percentage of participants with complete resolution of ≥ 1 tophi (using digital photography) at Week 52 in participants with tophi at baseline. Participants with resolution of ≥ 1 tophi at a visit are participants with resolution of ≥ 1 tophi at the visit (i.e. have complete response), and no progressive disease for any other tophi.

Time frame:
Baseline, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Resolution of ≥ 1 Tophi at Week 52
percentage of participantsPegloticase + MTXPegloticase + Placebo
Percentage of Participants With Complete Resolution of ≥ 1 Tophi at Week 5253.831.0
Statistical analysis
  • Pegloticase + MTX vs Pegloticase + Placebo · Chi-squared · p = 0.0482 (The comparison of complete response between groups is performed using an unstratified chi-squared test.) · Difference: 22.8 · 95% CI 1.2 to 44.4Difference (Pegloticase+MTX - Pegloticase+Placebo)
SecondaryMean Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52

HAQ-DI is a self-report functional status instrument that is filled out by the participant and measures disability over the past week via 20 questions relating to 8 domains of function: dressing, grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. The HAQ-DI ranges from 0 to 3 with higher values indicating higher disability. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
score on a scalePegloticase + MTXPegloticase + Placebo
Mean Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52-0.35 ± 0.049-0.31 ± 0.071
Statistical analysis
  • Pegloticase + MTX vs Pegloticase + Placebo · MMRM ANCOVA · p = 0.6287 (Based on mixed models repeated measures (MMRM) analysis of covariance (ANCOVA) model including the following terms: baseline value, tophi presence (Y/N), treatment group, visit, visit-by-treatment interaction, and visit-by-baseline value interaction.) · Difference: -0.04 · 95% CI -0.21 to 0.13Difference (Pegloticase+MTX - Pegloticase+Placebo)
SecondaryMean Change From Baseline HAQ Pain Score at Week 52

The HAQ-Pain score rates the participant's pain over the past week from 0 to 100 with 0 = no pain and 100 = severe pain. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline HAQ Pain Score at Week 52
score on a scalePegloticase + MTXPegloticase + Placebo
Mean Change From Baseline HAQ Pain Score at Week 52-31.02 ± 2.208-22.59 ± 3.230
Statistical analysis
  • Pegloticase + MTX vs Pegloticase + Placebo · MMRM ANCOVA · p = 0.0272 (Based on mixed models repeated measures (MMRM) analysis of covariance (ANCOVA) model including the following terms: baseline value, tophi presence (Y/N), treatment group, visit, visit-by-treatment interaction, and visit-by-baseline value interaction.) · Difference: -8.43 · 95% CI -15.88 to -0.97Difference (Pegloticase+MTX - Pegloticase+Placebo)
SecondaryMean Change From Baseline in HAQ Health Score at Week 52

The HAQ health scale is a self-reported measure of overall health. Participants are asked to rate how they are doing, considering all the ways arthritis affects them, on a scale of 0 to 100, where 0 represents very well and 100 represents very poor. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in HAQ Health Score at Week 52
score on a scalePegloticase + MTXPegloticase + Placebo
Mean Change From Baseline in HAQ Health Score at Week 52-28.85 ± 2.531-18.69 ± 3.722
Statistical analysis
  • Pegloticase + MTX vs Pegloticase + Placebo · MMRM ANCOVA · p = 0.0222 (Based on mixed models repeated measures (MMRM) analysis of covariance (ANCOVA) model including the following terms: baseline value, tophi presence (Y/N), treatment group, visit, visit-by-treatment interaction, and visit-by-baseline value interaction.) · Difference: -10.16 · 95% CI -18.84 to -1.48Difference (Pegloticase+MTX - Pegloticase+Placebo)

Adverse events

Collected over All Cause Mortality: from signing of informed consent up to Week 52 plus 30 days after last pegloticase infusion (±3 days). Adverse events (AEs)in the Run-in Period: Week -6 up to Day 1 (predose). AEs in the Pegloticase + IMM Period: Day 1 up to Week 52 plus 30 days after last pegloticase infusion (±3 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MTX: Methotrexate Tolerability Assessment Period0/159 (0%)0/159 (0%)45/159 (28.3%)
Pegloticase + MTX: Run-In Period0/98 (0%)1/98 (1%)28/98 (28.6%)
Pegloticase + Placebo: Run-In Period0/51 (0%)0/51 (0%)10/51 (19.6%)
Pegloticase + MTX: Pegloticase + IMM Period2/96 (2.1%)13/96 (13.5%)71/96 (74%)
Pegloticase + Placebo: Pegloticase + IMM Period0/49 (0%)5/49 (10.2%)42/49 (85.7%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventMTX: Methotrexate Tolerability Assessment PeriodPegloticase + MTX: Run-In PeriodPegloticase + Placebo: Run-In PeriodPegloticase + MTX: Pegloticase + IMM PeriodPegloticase + Placebo: Pegloticase + IMM Period
Anaphylactic ReactionImmune system disorders0/1590/980/511/962/49
Covid-19Infections and infestations0/1590/980/512/960/49
Inappropriate Antidiuretic Hormone SecretionEndocrine disorders0/1590/980/510/961/49
Non-Cardiac Chest PainGeneral disorders0/1590/980/510/961/49
Abscess Soft TissueInfections and infestations0/1590/980/510/961/49
Facial Bones FractureInjury, poisoning and procedural complications0/1590/980/510/961/49
Subdural HaematomaInjury, poisoning and procedural complications0/1590/980/510/961/49
Failure To ThriveMetabolism and nutrition disorders0/1590/980/510/961/49
Subarachnoid HaemorrhageNervous system disorders0/1590/980/510/961/49
SyncopeNervous system disorders0/1590/980/510/961/49
Most frequent other events
Most frequent other events
EventMTX: Methotrexate Tolerability Assessment PeriodPegloticase + MTX: Run-In PeriodPegloticase + Placebo: Run-In PeriodPegloticase + MTX: Pegloticase + IMM PeriodPegloticase + Placebo: Pegloticase + IMM Period
GoutMetabolism and nutrition disorders45/15928/9810/5164/9635/49
Infusion related reactionInjury, poisoning and procedural complications0/1590/980/511/9613/49
ArthralgiaMusculoskeletal and connective tissue disorders0/1590/980/5113/965/49
NauseaGastrointestinal disorders0/1590/980/515/966/49
VomitingGastrointestinal disorders0/1590/980/510/964/49
COVID-19Infections and infestations0/1590/980/517/963/49
Pain in extremityMusculoskeletal and connective tissue disorders0/1590/980/511/963/49
HypertensionVascular disorders0/1590/980/511/963/49
FatigueGeneral disorders0/1590/980/515/962/49
Back painMusculoskeletal and connective tissue disorders0/1590/980/515/962/49

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pegloticase + MTXPegloticase + PlaceboTotal
Mean55.6 ± 12.7453.0 ± 12.1254.7 ± 12.56
Sex: Female, Male
Sex: Female, Male(Participants)Pegloticase + MTXPegloticase + PlaceboTotal
Female9817
Male9144135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegloticase + MTXPegloticase + PlaceboTotal
Hispanic or Latino19928
Not Hispanic or Latino8142123
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegloticase + MTXPegloticase + PlaceboTotal
American Indian or Alaska Native000
Asian8614
Black or African American16622
Native Hawaiian or Other Pacific Islander415
White6936105
Other, Not Specified325
Missing011
08

Study locations

60 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • Orthopedic Physicians Alaska
    Anchorage, Alaska 99508, United States
  • Arizona Arthritis and Rheumatology Research, PLLC - Flagstaff
    Flagstaff, Arizona 86001, United States
  • Arizona Arthritis and Rheumatology Research, PLLC-West
    Glendale, Arizona 85306, United States
  • Arizona Arthritis and Rheumatology Research, PLLC-East
    Mesa, Arizona 85210, United States
  • Applied Research Center of Arkansas, Inc
    Little Rock, Arkansas 72212, United States
  • TriWest Research Associates
    El Cajon, California 92020, United States
  • Advanced Investigative Medicine, Inc.
    Hawthorne, California 90250, United States
  • Axis Clinical Trials
    Los Angeles, California 90036, United States
  • ACRC Studies
    Poway, California 92064, United States
  • ClinEdge Sierra Rheumatology, Inc.
    Roseville, California 95661, United States
  • East Bay Rheumatology Medical Group, Inc.
    San Leandro, California 94578, United States
  • Providence St. John's Health Clinic
    Santa Monica, California 90404, United States
  • Medvin Clinical Research
    Tujunga, California 91042, United States
  • San Fernando Valley Health Institute
    Van Nuys, California 91405, United States
  • Ventura Clinical Trials
    Ventura, California 93003, United States
  • University of Colorado Division of Rheumatology
    Aurora, Colorado 80045, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • Avail Clinical Research
    DeLand, Florida 32720, United States
  • Prohealth Research Center
    Doral, Florida 33166, United States
  • Omega Research Maitland
    Orlando, Florida 32808, United States
  • DMI Research
    Pinellas Park, Florida 33782, United States
  • Napa Research Center
    Pompano Beach, Florida 33064, United States
  • GCP Clinical Research
    Tampa, Florida 33609, United States
  • Florida Medical Clinic, LLC
    Zephyrhills, Florida 33542, United States
  • St. Luke's Clinic - Rheumatology
    Meridian, Idaho 83642, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Infusion Associates
    Grand Rapids, Michigan 49525, United States
  • Clinical Research Institute of Michigan, LLC
    Saint Clair Shores, Michigan 48081, United States
  • Benefis Hospital
    Great Falls, Montana 59405, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Santa Fe Rheumatology
    Santa Fe, New Mexico 87505, United States
  • Long Island Arthritis & Osteoporosis Care
    Babylon, New York 11702, United States
  • Buffalo Rheumatology and Medicine
    Orchard Park, New York 14127, United States
  • NorthEast Rheumatology/Atrium Health
    Concord, North Carolina 28025, United States
  • NorthEast Rheumatology
    Concord, North Carolina 28025, United States
  • Medication Management, LLC
    Greensboro, North Carolina 27408, United States
  • ClinEdge PMG Research of Hickory, LLC
    Hickory, North Carolina 28602, United States
  • ClinEdge PMG Research of Salisbury, LLC
    Salisbury, North Carolina 28144, United States
  • Shelby Clinical Research, LLC
    Shelby, North Carolina 28150, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Premier Clinical/STAT Research
    Dayton, Ohio 45417, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Source Inc.
    Perrysburg, Ohio 43551, United States
  • Premier Clinical/STAT Research - Springboro
    Springboro, Ohio 45066, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Piedmont Arthritis Clinic
    Greenville, South Carolina 29601, United States
  • Articularis Healthcare Group
    Summerville, South Carolina 29486, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Ramesh C. Gupta, M.D.
    Memphis, Tennessee 38119, United States
  • Diagnostic and Interventional Nephrology Of Houston
    Houston, Texas 77004, United States
  • Research Consultants - Frostwood
    Houston, Texas 77024, United States
  • Research Consultants - Astoria
    Houston, Texas 77089, United States
  • Arthritis Clinic of Central Texas
    San Marcos, Texas 78666, United States
  • Arthritis & Osteoporosis Clinic - Waco
    Waco, Texas 76710, United States
  • Clear Lake Specialties
    Webster, Texas 77598, United States
  • Western Washington Arthritis Clinic
    Bothell, Washington 98021, United States
  • Arthritis Northwest
    Spokane, Washington 99204, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53219, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Mar 2021, 21 months.

Results were first posted in May 2022, 1 year 1 month after primary completion.

Of 18 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2019
First posted
Jun 21, 2019
StartActual
Jun 13, 2019
Primary completionActual
Mar 17, 2021
CompletionActual
Apr 11, 2022
Results first posted
May 16, 2022
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03994731
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 21, 2019
Start date
Jun 13, 2019
Primary completion
Mar 17, 2021
Completion
Apr 11, 2022
Results posted
May 16, 2022
Last update
Jun 26, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegloticase · Methotrexate

Start the discussion